key: cord-0966069-a5wnaijy
authors: Zhou, Mei; Yin, Zhengrong; Xu, Juanjuan; Wang, Sufei; Liao, Tingting; Wang, Kai; Li, Yumei; Yang, Fan; Wang, Zhen; Yang, Guanghai; Zhang, Jianchu; Yang, Jin
title: Inflammatory profiles and clinical features of COVID-19 survivors three months after discharge in Wuhan, China
date: 2021-04-04
journal: J Infect Dis
DOI: 10.1093/infdis/jiab181
sha: b2c395c8b256809d535f385d719f59351f57a522
doc_id: 966069
cord_uid: a5wnaijy

BACKGROUND: Post-discharge immunity and its correlation with clinical features among patients recovered from COVID-19 are poorly described. This prospective cross-sectional study explored the inflammatory profiles and clinical recovery of COVID-19 patients at 3 months post-discharge. METHODS: COVID-19 patients discharged from four hospitals in Wuhan, recovered asymptomatic patients (APs) from an isolation hotel, and uninfected healthy controls (HCs) were recruited. Viral nucleic acid and antibody detection, laboratory examination, computed tomography, pulmonary function assessment, multiplex cytokine assay, and flow cytometry were performed. RESULTS: The 72 age-, sex- and body mass index-matched participants included 19 severe/critical patients (SPs), 20 mild/moderate patients (MPs), 16 APs, and 17 HCs. At 3 months after discharge, levels of pro-inflammatory cytokines and factors related to vascular injury/repair in recovered COVID-19 patients had not returned to those of the HCs, especially among recovered SPs compared to recovered MPs and APs. These cytokines were significantly correlated with impaired pulmonary function and chest CT abnormalities. However, levels of immune cells had returned to nearly normal levels and were not significantly correlated with abnormal clinical features. CONCLUSION: Vascular injury, inflammation, and chemotaxis persisted in COVID-19 patients and were correlated with abnormal clinical features 3 months after discharge, especially in recovered SPs.

The ongoing coronavirus disease 2019 (COVID- 19) pandemic has, as of November 12, 2020, caused >50 million cases and over 1,275,000 deaths [1] , posing an overwhelming threat to global health. With the increasing number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, the recovery state, regardless of asymptomatic, mild, or severe infections, has attracted attention. Determining the long-term clinical outcome and longevity of the inflammatory state after SARS-CoV-2 infection is critical for understanding the disease spectrum of COVID-19 and optimizing post-COVID-19 rehabilitation.

The immunopathology of COVID-19 is a serious issue [2] . In patients with severe COVID-19, lymphopenia is frequently observed, with reduced numbers of CD4+ T, CD8+ T, B, and natural killer (NK) cells and reduced percentages of monocytes and eosinophils [3, 4] . Most patients with severe COVID-19 exhibit elevated serum levels of pro-inflammatory cytokines, including interleukin (IL)-6 and IL-1β, as well as IL-2, IL-8, IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ-inducible protein-10 (IP-10), monocyte chemotactic protein (MCP), macrophage inflammatory protein (MIP)-1α, and tumor necrosis factor (TNF)-α, which are characterized as cytokine storms [3] [4] [5] . Moreover, specific proinflammation markers are strongly correlated with worse outcomes and death in COVID-19 patients [6, 7] , suggesting that poor clinical outcomes might be attributed to viral-driven hyperinflammation. However, how this pathological immunity will evolve and whether it is related to undesirable sequelae among discharged COVID-19 patients remains unknown.

Two recent studies reported that the levels of immune cells, including neutrophils, monocytes, NK cells, and B and T lymphocytes, returned to nearly baseline levels in recovered untreated COVID-19 individuals [8, 9] . Convalescent-phase SARS-CoV-2-specific T cells are polyfunctional and display a stem-like memory phenotype [10] . However, the A c c e p t e d M a n u s c r i p t 6 recovery time after patient discharge was not unified in these studies, and few reports have focused on the recovery of soluble pro-inflammatory, chemotaxis, and endothelial-injuryrelated markers, which is important for understanding patient immune outcomes and formulating rehabilitation strategies for recovered patients. Thus, this study explored the immunological profiles and clinical characteristics of recovered COVID-19 patients with different disease severities 3 months after discharge and analyzed the correlations between aberrant levels of immune markers and abnormal clinical features to provide more rational guidance for future follow-up and rehabilitation.

This prospective cross-sectional study involved COVID-19 patients discharged between March 5 and March 31, 2020, from four hospitals in Wuhan (Wuhan Union Hospital, Wuhan Pulmonary Hospital, Wuhan Central Hospital, and Fangcang Hospital), as well as recovered asymptomatic patients (APs) from an isolation hotel and uninfected healthy controls (HCs) in the community. Recruitment and testing were carried out in the outpatient clinic of Wuhan Union Hospital via telephone at 3 months after discharge by trained medical staff. All patients were contacted in the order of their discharge dates, as documented in their medical records. The exclusion criteria were chronic respiratory, hematological, autoimmune, and psychotic diseases; death before follow-up; declining to participate, or an inability to participate for reasons such as living outside Wuhan city or inability to be contacted. The recovered APs were confirmed by a previous positive SARS-CoV-2 nucleic acid test or current positive SARS-CoV-2 antibody test without symptoms throughout. Age, sex, and body mass index (BMI) were matched between the recovered COVID-19 patients and healthy A c c e p t e d M a n u s c r i p t 7 controls (recruitment details are shown in Figure S1 ). [11] . When interviewed, the participants were subjected to a physical checkup, pulmonary-function test, and chest computed tomography (CT) scan.

Routine blood tests, biochemical tests (renal and live function markers), and coagulation tests were also completed, with peripheral venous blood samples collected for the subsequent measurement of immune cell and cytokine levels.

This project was registered on the Clinical Trials website (No. NCT04456101), and has been approved by the institutional review boards of Medical Ethics Committee of Wuhan Union Hospital (NO.0271-01). All participants or their surrogates signed informed consent.

The standard protocols were as previously reported [12] [13] [14] [15] , and are described in detail in the Supplementary Methods.

Peripheral venous blood was collected into ethylenediaminetetraacetic acid (EDTA)-coated vacutainer tubes. Supernatant was obtained subsequently for cytokine profiling assays. (VEGF)-A, VEGF-C, VEGF-D, vascular endothelial growth factor   receptor-1 (Flt-1), GM-CSF, IL-2, IL-4, IL-5, IL-7, IL-9, IL-15, thymic stromal lymphopoietin (TSLP), serum amyloid A protein (SAA), interferon-γ (IFN-γ), TNF-α, TNFβ, IL-1α, IL-1β, IL-1RA, IL-6, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-17A, IL-17B, IL 

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood via standard density gradient centrifugation and were used immediately. The isolated PBMCs were stained with fluorochrome-conjugated human monoclonal antibodies (all from BD Biosciences, USA, Table S1 ) to determine the percentage of immune cells in PBMCs; that is, T lymphocytes (anti-CD3, CD4, CD8), natural killer (NK) cells, NKT cells, macrophages, dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), and their subsets. Cell acquisition was performed on a BD LSRFortessa X-20 flow cytometer (BD Biosciences).

Data were analyzed using FlowJo V10 software.

The clinical characteristics and inflammatory consequences of all participants are presented as medians (IQR) or means (± SD) for continuous variables and absolute values with percentages for categorical variables. For the comparison of clinical characteristics (laboratory findings, pulmonary function, and CT scans), percentage of immune cells, and 44 cytokines between the four groups (recovered SPs, MPs, APs, and HCs), we used Kruskal-A c c e p t e d M a n u s c r i p t 9 (data with normal distribution), χ2 tests, or Fisher's exact tests, as appropriate, to obtain an overall p-value for each variable. To adjust for multiple hypothesis testing, false discovery rate (FDR) correction was first performed for the overall p-value using the Benjamini-Hochberg procedure at the FDR <0.05 significance threshold. Then, for variables with an overall p <0.05 and FDR <0.05, which were deemed statistically significant, we performed pairwise subgroup comparisons (recovered SPs vs. HCs, MPs vs. HCs, APs vs. HCs, SPs vs.

MPs, SPs vs. APs, and MPs vs. APs). We conducted Mann-Whitney U test (data with nonnormal distribution), independent t-test (data with normal distribution), χ2, and Fisher's exact tests as appropriate, with Bonferroni correction and took the two-sided p <0.05/n (n = the number of comparisons) as the threshold to determine whether the comparison between the two subgroups was statistically significant. The associations between cytokine profiles and abnormal clinical features in recovered COVID-19 patients were examined by Spearman correlation analysis and visualized with correlation matrix plots.

All tests were two-sided and performed using R software (version 4.0.2, R Foundation) or SPSS (version 26).

This study enrolled three groups of COVID-19 patients at 3 months after discharge (recovered SPs: n= 19; recovered MPs: n=20; and recovered APs: n=16). Seventeen HCs were recruited at the same time and were matched for age, sex, and BMI. As shown in Table   1 , the mean duration from illness onset to follow-up was 4. IgM. The laboratory findings of the four groups revealed that all indicators had returned to normal levels and were comparable to those in the HCs. Comparison of levels of C-reactive protein (CRP) and some hematologic markers at discharge and 3 months later revealed that only the monocyte counts were significantly decreased after 3 months (Table S2) . Artificial intelligence (AI)-assisted CT findings showed persisting residual lesions on chest CT images and were more frequently observed in recovered SPs (94.7%), followed by recovered MPs (80%). Consistently, the volume percentages of total lesion, ground-glass opacity (GGO), and solid component in the lungs increased with the severity of previous COVID-19. In general, the volume of residual lesions in the whole lungs was not large, indicating that the pneumonia lesions on CT images were well absorbed in recovered COVID-19 patients 3 months after discharge. However, strip-like fibrosis, a solid component newly formed during the recovery period, was more common in recovered SPs than in MPs (89.5% vs. 30%). Correspondingly, anomalies of pulmonary function were mainly noted in diffusion capacity and lung volume ( Table 1) , as revealed by the significantly reduced diffusing capacity for carbon monoxide (DLCO)%, total lung capacity (TLC)%, and residual volume (RV)% values in the recovered SPs, but not in MPs and APs. The ventilatory capacity of pulmonary function showed no significant differences (Table S3 ).

The abnormal clinical manifestations above indicated that the COVID-19 survivors had not yet fully recovered at 3 months after hospital discharge and had suffered post-COVID-19

organ damage (fibrosis on CT images and decreased lung volume and DLCO pred%). To assess the state of inflammation in these survivors, we measured the levels of 44 plasma cytokines in SPs, MPs, Aps, and HCs using an MSD multiplexed immunoassay (Figure 1-4) .

The plasma cytokines were categorized into four classes.

A c c e p t e d M a n u s c r i p t 11 Class-1 cytokines are associated with vascular injury and repair/angiogenesis ( Figure 1 ). We discovered that VCAM-1, ICAM-1, PlGF, and Tie-2 were significantly elevated in recovered SPs compared to HCs, whereas bFGF exhibited the opposite change, but MPs and APs bore no significant difference with HCs. Meanwhile, VEGF family and its receptor Flt-1 showed no significant differences between these four groups ( Figure 1C ).

Class-2 cytokines promote immune cell growth and differentiation (Figure 2) . Comparison of these cytokines revealed that IL-7 levels significantly decreased in recovered SPs compared to those in APs and HCs, while TSLP levels were relatively higher in recovered SPs. However, no significant differences were found in GM-CSF, IL2, IL-4, IL-5, IL-9, and IL-15. IL-7 exerts anti-apoptotic properties and induces potent proliferation of naive and memory T cells, causing replenishment of the circulating pool (CD4 + and CD8 + ) [16, 17] . TSLP is reportedly involved in the development of acute Th2-dependent allergic airway inflammation [18] . Accordingly, recovered SPs tended to have a certain degree of T cell immune perturbation. (stimulates a migratory response in CD4 + lymphocytes) did not differ significantly among the four groups.

Moreover, among these 44 cytokines, only VCAM-1, ICAM-1, TNF-α, MIP-1α, and MIP-1β

were significantly higher in recovered SPs than in recovered MPs.

Several plasma cytokines remained at abnormal levels in recovered COVID-19 patients 3 months after discharge, especially in recovered SPs, which prompted consideration of immune cell recovery. We explored the proportions of six types of immune cells (T, NK, NKT, DC, macrophage, and MDSC) by isolating PBMCs from whole blood and phenotypically analyzed them by flow cytometry ( Figure S2 ). As shown in Table 2 , a total of 51 age-, sex-, and BMI-matched subjects were analyzed (recovered SPs: n=20; MPs n=14;

APs: n=9; HCs: n=8). The proportions of total CD3 + T, CD4 + T, CD8 + T cells, NK, and NKT cells were slightly higher in the recovered SPs at 3 months after discharge, with the ratio of CD4 + /CD8 + T cells relatively lower than that in HCs, although the differences were not statistically significant. Similarly, no significant difference was observed in the percentage of DCs (CD11C + HLA-DR + ) between recovered COVID-19 individuals and HCs. The mean fluorescence intensity (MFI) of CD80 and CD86 in DCs was comparable across the four groups. We also did not observe any significant differences in the percentages of macrophages (CD11b + CD14 + ) and the CD80 and CD86 MFIs of macrophages between A c c e p t e d M a n u s c r i p t 13 We further divided the recovered COVID-19 patients into two groups according to the results of DLCO% and CT scans. However, none of the immune cells exhibited significant differences between the group with normal DLCO% (NDLCO) and abnormal DLCO% group (ADLCO) (Figure S3) , while the proportion of CD4 + T cells and PMN-MDSC was significantly lower in the abnormal CT group (ACT) than in the normal CT group (NCT) ( Figure S4 ).

Based on the above findings, we examined the potential associations between cytokine profiles and abnormal clinical features by Spearman correlation analysis in recovered COVID-19 patients. Variables with significant correlations are shown in Figure 5 and Table   S4 

The results of this study showed persisting respiratory sequelae (reduced lung volume, Furthermore, dysfunction of myeloid, NK, T, and B cells and their subsets occur in acutephase COVID-19 [29] [30] [31] . In this study, we found that immune cells, including DCs, macrophages and their CD80 and CD86 MFI, as well as NK, NKT cells, T cells (total, CD4 + , CD8 + ), and MDSCs (total, PMN-, MO-), returned to normal levels in recovered COVID-19 patients 3 months after discharge. These data were consistent with those of a recent study [8] that reported comparable numbers of CD4 + T, CD8 + T cells, B cells, and NK cells in 

Anonymized clinical and laboratory test data are available on request, subject to an internal review by YJ and MZ to ensure that the participants' anonymity and confidentiality are protected, with completion of a data-sharing agreement, and in accordance with the Wuhan Union hospital's institutional review boards and institutional guidelines. Please submit requests for participant-related clinical and other data to YJ (whuhjy@126.com).

The authors have no conflict of interest or financial relationships to disclose. A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t Bonferroni correction method, and the significance was indicated as: ns, not significant; *p < 0.0083 (0.05/6), **p < 0.0017 (0.01/6), ***p < 0.00017 (0.001/6), ****p < 0.000017 (0.0001/6). recovered APs (green) or HCs (blue). Significance of comparisons of the four groups was determined by the Kruskal-Wallis test (data with non-normal distribution) or oneway ANOVA (data with normal distribution) and presented as an absolute overall p value. False discovery rate (FDR) correction was first applied for all the 44 cytokines.

For variables with overall p value < 0.05 and FDR < 0.05, pairwise subgroup comparison (recovered SPs vs. HCs, MPs vs. HCs, APs vs. HCs, SPs vs. MPs, SPs vs.

APs, and MPs vs. APs) was performed with Bonferroni correction method, and the significance was indicated as: ns, not significant; *p < 0.0083 (0.05/6), **p < 0.0017 (0.01/6), ***p < 0.00017 (0.001/6), ****p < 0.000017 (0.0001/6). (red), recovered MPs (brown), recovered APs (green) or HCs (blue). Significance of comparisons of the four groups was determined by the Kruskal-Wallis test (data with non-normal distribution) or one-way ANOVA (data with normal distribution) and presented as an absolute overall p value. False discovery rate (FDR) correction was first applied for all the 44 cytokines. For variables with overall p value < 0.05 and FDR < 0.05, pairwise subgroup comparison (recovered SPs vs. HCs, MPs vs. HCs, APs vs. HCs, SPs vs. MPs, SPs vs. APs, and MPs vs. APs) was performed with Bonferroni correction method, and the significance was indicated as: ns, not significant; *p < 0.0083 (0.05/6), **p < 0.0017 (0.01/6), ***p < 0.00017 (0.001/6), ****p < 0.000017 (0.0001/6). and RV pred%). These correlations were calculated by 55 recovered COVID-19 patients pooled as one group, using the value of each variable for each patient. Only cytokines of significant correlations were displayed. Significance was determined by two-tailed, Spearman correlation analysis: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. And the correlation coefficients were visualized by colour intensity and dot size.

WHO. Coronavirus Disease (COVID-19) Dashboard. 2021

COVID-19: immunopathology and its implications for therapy

Clinical infectious diseases : an official publication of the Infectious Diseases Society of

Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Comprehensive mapping of immune perturbations associated with severe COVID-19

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

(ncov)-infection-is-suspected. Clinical management of COVID-19. Interim guidance

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients

Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations

Immunotherapeutic effects of IL-7 during a chronic viral infection in mice

Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation

TSLP drives acute T(H)2-cell differentiation in lungs

COVID-19: consider cytokine storm syndromes and immunosuppression

Cytokine release syndrome in severe COVID-19

COVID-19 is, in the end, an endothelial disease

SARS-CoV-2: a storm is raging

Coronavirus infections and immune responses

Immunology of COVID-19: Current State of the Science

Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections

Immune monitoring of

compassionate use in a critically ill COVID-19 patient

Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease

The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe?

Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

A c c e p t e d M a n u s c r i p t